Home / Health / Diabetes Drugs Linked to Rare Eye Risk
Diabetes Drugs Linked to Rare Eye Risk
20 Jul
Summary
- GLP-1 agonists may increase risk of optic neuropathy.
- Study found a small increase in cases per 10,000 patients.
- Vision loss can be rapid and permanent, researchers warn.
Medications widely used for type 2 diabetes and obesity, known as GLP-1 receptor agonists, are associated with a slight rise in the risk of ischemic optic neuropathy. This rare condition occurs when blood flow to the optic nerve is abruptly reduced, potentially leading to swift and irreversible partial vision loss.
The study, published in Annals of Internal Medicine, observed an increase of roughly three to four cases for every 10,000 patients treated with these drugs over an 18-month period. This compared to individuals taking other diabetes medications, SGLT2 inhibitors or DPP4 inhibitors. Researchers emphasized that the actual risk to individuals remains low and may be influenced by underlying health conditions of the study participants, all of whom had type 2 diabetes.
While the association is being noted by the medical community, further investigation is needed to confirm the causal link. The condition typically manifests as blurred or dimming vision in one eye, or a loss of a portion of the visual field. Early recognition and prompt ophthalmologic evaluation are crucial, especially for patients with a higher baseline risk.
